Fedratinib

(Inrebic®)

Fedratinib

Drug updated on 9/4/2024

Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Inrebic (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Spleen Volume Reduction and Total Symptom Score Reduction in Myelofibrosis: Fedratinib and ruxolitinib were confirmed as effective for spleen volume reduction and symptom score reduction in a systematic review and network meta-analysis of 1953 patients. Momelotinib showed comparable efficacy to ruxolitinib, with reduced toxicity in erythrocytes and platelets.
  • Mortality and Clinical Improvement in COVID-19: The meta-analysis of 1190 hospitalized COVID-19 patients indicated that JAK inhibitors, including fedratinib, were associated with a reduced risk of mortality (OR 0.51) and improved clinical outcomes (OR 1.76).
  • Fedratinib and ruxolitinib exhibited distinct tolerance profiles, with Momelotinib showing a favorable effect on anemia. Pacritinib demonstrated higher toxicity concerning erythrocytes and platelets compared to Momelotinib in myelofibrosis patients.
  • The safety outcomes were not explicitly discussed in the study on COVID-19 treatment, and no comparative safety analysis among the JAK inhibitors was provided.
  • There is no population or subgroup information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Inrebic (fedratinib) Prescribing Information.2023Bristol-Myers Squibb, New York, NY

Systematic Reviews / Meta-Analyses